Testing the right target and right drug at the right stage.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22133718.
- Also identified by DOI 10.1126/scitranslmed.3002609 and PMC identifier 3752906.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?
Medical subject headings
- Alzheimer Disease
- Molecular Targeted Therapy